Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor

被引:23
|
作者
Minich, WB [1 ]
Lenzner, C [1 ]
Morgenthaler, NG [1 ]
机构
[1] BRAHMS AG, Res Dept, Biotechnol Ctr Hennigsdorf Berlin, D-16761 Hennigsdorf, Germany
关键词
epitopes; TBAb; TSAb; TSH receptor; TRAb;
D O I
10.1111/j.1365-2249.2004.02417.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The hyperthyroidism of Graves' disease (GD) is caused by TSH-receptor (TSH-R) stimulating autoantibodies (TSAb), leading to overproduction of thyroid hormones. We present evidence for TSAb interaction with three distinct regions of the TSH-R, one in immediate vicinity of the carboxy terminal serpentine. Three murine monoclonal antibodies (MoAbs 28.1, A9 and 31.7) directed to amino acids 36-40, 147-228 and 382-415 were labelled and tested for their binding to human recombinant TSH-R on solid phase. All MoAbs bound to TSH-R with a K-d of 8-12 nM and showed no competition among themselves. We tested 114 sera from euthyroid controls, 118 TBII positive sera from patients with GD (containing TSAb confirmed by bioassays), 16 TBII positive sera from patients with autoimmune thyroid disease (AIT), who were hypothyroid and had TSH blocking antibodies (TBAb), and 20 patients with AIT, who were hypothyroid but negative for all TRAb. Mid-regional MoAb A9 tracer achieved the highest sensitivity in the GD group (72.0%), whereas C-terminal MoAb 31.7 found most sera positive in the AIT group (87.5%). Surprisingly, the N-terminal MoAb 28.1 had the lowest sensitivity in the GD (10.4%) and AIT group (43.8%). Using a mixture of all three tracer MoAbs did not increase the sensitivity in the GD or AIT group, compared to the best single MoAb alone. Median inhibition of MoAb A9 was significantly (P < 0.001) higher than inhibition of MoAbs 28.1 or 31.7 in the group of GD patients but not in other groups. Almost all patient sera with positive reactivity in the MoAb tracer assays had TBII values in the higher range. However, there were many highly TBII positive sera, which did not show a displacement of the MoAb tracers. We conclude that, contrary to some reports, the binding of TSAb and TBAb to the TSH-R is not restricted to distinct and distant epitopes. The middle part of the TSH-R seems to be more relevant for TSAb binding than the N-terminal part, while a proportion of TSAb autoantibodies also binds to a C-terminal epitope of the TSH-R. The method described here is a TSH independent competitive assay for the detection of TSH-R autoantibodies.
引用
收藏
页码:129 / 136
页数:8
相关论文
共 28 条
  • [21] Remission Rate of Graves' Disease and the Trend of Changes in Serum TSH Receptor Antibodies in Prolonged Antithyroid Drug Treatment
    Villagelin, Danilo
    Santos, Roberto Bernardo
    Romaldini, Joao Hamilton
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 18
  • [22] Antibodies against thyroid-stimulating hormone receptor cause maternal-neonatal transmission of Graves' Disease
    Yu, Yue
    Liu, Qian-Qi
    Liu, De-Yun
    Wang, Dan-Dan
    Yang, Li-Qi
    Ye, Shu-Ming
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
  • [23] Clinical validity of intercellular adhesion molecule-1 (ICAM-1) and TSH receptor antibodies in sera from patients with Graves' disease
    Massart, C
    Sonnet, E
    Gibassier, J
    Maugendre, D
    Genetet, B
    CLINICA CHIMICA ACTA, 1997, 265 (02) : 157 - 168
  • [24] Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease
    Kubota, S
    Ohye, H
    Nishihara, E
    Kudo, T
    Ito, M
    Fukata, S
    Amino, N
    Kuma, K
    Miyauchi, A
    ENDOCRINE JOURNAL, 2005, 52 (06) : 735 - 741
  • [25] A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model
    Diana, Tanja
    Ungerer, Martin
    Wuster, Christian
    Fassbender, Julia
    Li, Zhongmin
    Reimann, Andreas
    Holthoff, Hans-Peter
    Kanitz, Michael
    Kahaly, George J.
    JOURNAL OF AUTOIMMUNITY, 2021, 122
  • [26] Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves' disease
    Ren, Xuan
    Chen, Hui
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease
    Izumi, Y
    Takeoka, K
    Amino, N
    ENDOCRINE JOURNAL, 2005, 52 (04) : 493 - 497
  • [28] A Novel Bioreporter Assay for Thyrotropin Receptor Antibodies Using a Chimeric Thyrotropin Receptor (Mc4) Is More Useful in Differentiation of Graves' Disease from Painless Thyroiditis Than Conventional Thyrotropin-Stimulating Antibody Assay Using Porcine Thyroid Cells
    Kamijo, Keiichi
    Murayama, Hiroshi
    Uzu, Takahiro
    Togashi, Kazuyoshi
    Kahaly, George J.
    THYROID, 2010, 20 (08) : 851 - 856